Hemostatic therapy for treatment of oral anticoagulation-related ICH

More documents

Recommendations

Info

Other risks of FFP • Circulatory overload • Blood-borne infection – HIV, HCV, HBV • Allergic reactions
Recombinant activated Factor VII • 5µg/kg (1 mg for 100 kg patient) corrects therapeutic INR in minutes But- • Replaces only 1 factor – may not correct coagulopathy • rFVIIa interferes with INR assay – INR no longer reflects bleeding tendency – No way to monitor need for additional treatment
Page 1 and 2: Hemostatic therapy for treatment of
Page 3 and 4: The Controversy Should PCC or rFVII
Page 5 and 6: Larger size predicts worse outcome
Page 7 and 8: Goal: Rapid correction of warfarin
Page 9 and 10: Vitamin K • Takes hours to days t
Page 11: Transfusion related acute lung inju
Page 15 and 16: FVIIa normalizes INR but not bleedi
Page 17 and 18: Literature review: PCC for warfarin
Page 19 and 20: FFP vs. PCC in OAC-related ICH •
Page 21 and 22: Survey of practice • Treat a hypo
Page 23: Conclusions • Give vitamin K •

Hemostatic therapy for treatment of oral anticoagulation-related ICH

Create successful ePaper yourself

Delete template?

Save as template?